What is Palisade Bio Inc's earnings per share (EPS)?

Palisade Bio Inc (PALI) reported diluted earnings per share of $-0.30 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Palisade Bio Inc Financials

PALI

Source SEC Filings (10-K/10-Q) Updated Mar 20, 2026 Currency USD FYE March

This page shows Palisade Bio Inc (PALI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Palisade Bio Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.65x

For every $1 of reported earnings, Palisade Bio Inc generates $0.65 in operating cash flow (-$10.8M OCF vs -$16.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1805.6x

Palisade Bio Inc earns $-1805.6 in operating income for every $1 of interest expense (-$18.1M vs $10K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$18.1M

YoY-21.5%

Palisade Bio Inc's EBITDA was -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.5% from the prior year.

Net Income

-$16.8M

YoY-16.2%

Palisade Bio Inc reported -$16.8M in net income in fiscal year 2025. This represents a decrease of 16.2% from the prior year.

EPS (Diluted)

$-0.30

Palisade Bio Inc earned $-0.30 per diluted share (EPS) in fiscal year 2025. This represents an increase of 97.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$133.4M

YoY+1258.2%

5Y CAGR+184.7%

10Y CAGR+39.7%

Palisade Bio Inc held $133.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

166M

Palisade Bio Inc had 166M shares outstanding in fiscal year 2025. This represents an increase of 5891.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-13.0%

YoY+179.7pp

10Y CAGR+407.9pp

Palisade Bio Inc's ROE was -13.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 179.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$16.0M

YoY+76.5%

5Y CAGR+51.3%

10Y CAGR+2.4%

Palisade Bio Inc invested $16.0M in research and development in fiscal year 2025. This represents an increase of 76.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

PALI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$0-100.0%	$250K	$0	N/A	$14K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$16.0M+76.5%	$9.1M+31.5%	$6.9M+5.3%	$6.5M+169.4%	$2.4M+20.4%	$2.0M
SG&A Expenses	$7.9M+35.7%	$5.8M-6.5%	$6.2M-29.2%	$8.8M-5.8%	$9.3M+50.2%	$6.2M
Operating Income	-$18.1M-21.5%	-$14.9M-13.7%	-$13.1M+16.9%	-$15.7M+62.4%	-$41.9M-350.2%	-$9.3M
Interest Expense	$10K-16.7%	$12K-20.0%	$15K+15.4%	$13K-99.5%	$2.4M+920.4%	$235K
Income Tax	N/A	$0	$0	$0	$0-100.0%	$1K
Net Income	-$16.8M-16.2%	-$14.4M-17.4%	-$12.3M+13.7%	-$14.3M+46.4%	-$26.6M-157.9%	-$10.3M
EPS (Diluted)	$-0.30	$-10.19	$-27.01	$-16.53	$-169.74	$-3.72

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0	$0	N/A	$0	$0	$0	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.4M-16.8%	$1.7M+76.3%	$950K	N/A	$16.0M+508.8%	$2.6M+18.7%	$2.2M+511.6%	$362K
SG&A Expenses	$1.5M+30.8%	$1.2M-14.1%	$1.4M	N/A	$1.5M-8.0%	$1.6M+8.5%	$1.5M	N/A
Operating Income	-$2.9M-2.8%	-$2.8M-23.1%	-$2.3M	N/A	-$3.6M+14.7%	-$4.2M-14.6%	-$3.7M	N/A
Interest Expense	$5K+150.0%	$2K+100.0%	$1K	N/A	$6K+200.0%	$2K+100.0%	$1K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.9M-3.0%	-$2.8M-24.8%	-$2.2M	N/A	-$3.5M+14.5%	-$4.1M-15.7%	-$3.5M	N/A
EPS (Diluted)	$-0.38	$-0.58-23.4%	$-0.47	N/A	$-2.32+30.1%	$-3.32	$-4.59	N/A

PALI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$134.3M+1134.8%	$10.9M-22.6%	$14.1M-10.9%	$15.8M+26.0%	$12.5M+314.4%	$3.0M
Current Assets	$134.2M+1179.0%	$10.5M-21.3%	$13.3M-9.5%	$14.7M+28.0%	$11.5M+1184.2%	$896K
Cash & Equivalents	$133.4M+1258.2%	$9.8M-21.0%	$12.4M+0.4%	$12.4M+18.0%	$10.5M+1371.9%	$713K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$0	$0-100.0%	$59K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.0M+46.5%	$3.4M+23.7%	$2.7M-16.6%	$3.3M-36.2%	$5.1M-73.8%	$19.6M
Current Liabilities	$4.6M+43.3%	$3.2M+25.1%	$2.6M-14.1%	$3.0M+20.7%	$2.5M-69.1%	$8.1M
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$94K
Total Equity	$129.4M+1626.9%	$7.5M-33.8%	$11.3M-9.3%	$12.5M+69.4%	$7.4M+144.4%	-$16.6M
Retained Earnings	N/A	$135.9M+11.9%	$121.5M+11.3%	$109.2M+15.4%	$94.6M+239.1%	-$68.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$7.0M+4.6%	$6.7M-18.6%	$8.2M-24.7%	$10.9M+16.5%	$9.3M-27.5%	$12.9M+1.7%	$12.7M-10.0%	$14.1M
Current Assets	$6.8M+5.9%	$6.4M-18.3%	$7.9M-24.8%	$10.5M+18.3%	$8.9M-28.0%	$12.3M+2.5%	$12.0M-9.9%	$13.3M
Cash & Equivalents	$5.2M-3.5%	$5.4M-25.1%	$7.2M-26.4%	$9.8M+22.2%	$8.0M-29.2%	$11.4M+0.7%	$11.3M-9.3%	$12.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.8M-7.1%	$4.0M+41.6%	$2.9M-15.6%	$3.4M+24.2%	$2.7M-6.6%	$2.9M+12.9%	$2.6M-5.5%	$2.7M
Current Liabilities	$3.5M-12.4%	$4.0M+43.0%	$2.8M-14.2%	$3.2M+20.7%	$2.7M-5.5%	$2.8M+15.0%	$2.5M-4.6%	$2.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.2M+22.6%	$2.6M-50.9%	$5.3M-28.8%	$7.5M+13.4%	$6.6M-33.6%	$9.9M-1.1%	$10.1M-11.0%	$11.3M
Retained Earnings	N/A	$141.0M+2.0%	$138.2M+1.7%	$135.9M+2.5%	$132.6M+202.7%	-$129.1M-3.3%	-$125.0M-202.9%	$121.5M

PALI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$10.8M+11.0%	-$12.2M-9.5%	-$11.1M+16.7%	-$13.4M+9.6%	-$14.8M-209.8%	-$4.8M
Capital Expenditures	N/A	$0-100.0%	$4K-60.0%	$10K	$0-100.0%	$6K
Free Cash Flow	N/A	-$12.2M-9.5%	-$11.1M+16.7%	-$13.4M+9.5%	-$14.8M-209.4%	-$4.8M
Investing Cash Flow	N/A	$0+100.0%	-$4K+60.0%	-$10K+81.5%	-$54K-800.0%	-$6K
Financing Cash Flow	$134.4M+1303.0%	$9.6M-14.3%	$11.2M-26.7%	$15.3M-38.0%	$24.6M+1202.1%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$3.6M-95.5%	-$1.8M+22.1%	-$2.3M+2.0%	-$2.4M+24.0%	-$3.1M+10.5%	-$3.5M-10.0%	-$3.2M-15.8%	-$2.7M
Capital Expenditures	N/A	N/A	N/A	$0	$0	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	-$2.4M+24.0%	-$3.1M	N/A	N/A	-$2.7M
Investing Cash Flow	N/A	N/A	N/A	$0	$0	N/A	N/A	$0
Financing Cash Flow	$3.4M+83975.0%	$4K+101.6%	-$258K-106.2%	$4.2M+2412.2%	-$180K-105.0%	$3.6M+76.7%	$2.0M+1610.4%	-$134K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PALI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-5228.0%	N/A	N/A	-68764.8%
Net Margin	N/A	N/A	-4920.0%	N/A	N/A	-76346.1%
Return on Equity	-13.0%+179.7pp	-192.7%-84.0pp	-108.7%+5.6pp	-114.3%+247.1pp	-361.4%	N/A
Return on Assets	-12.5%+120.2pp	-132.7%-45.2pp	-87.5%+2.9pp	-90.5%+122.3pp	-212.7%+129.2pp	-341.9%
Current Ratio	28.95+25.7	3.24-1.9	5.15+0.3	4.89+0.3	4.61+4.5	0.11
Debt-to-Equity	0.04-0.4	0.45+0.2	0.24-0.0	0.26+0.3	0.000.0	-0.01
FCF Margin	N/A	N/A	-4454.8%	N/A	N/A	-35310.7%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-89.3%+17.0pp	-106.3%-64.4pp	-41.8%	N/A	-52.8%-11.8pp	-41.0%-6.0pp	-35.0%	N/A
Return on Assets	-41.1%+0.6pp	-41.8%-14.5pp	-27.2%	N/A	-37.4%-5.6pp	-31.7%-3.8pp	-27.9%	N/A
Current Ratio	1.96+0.3	1.62-1.2	2.84-0.4	3.24-0.1	3.31-1.0	4.34-0.5	4.87-0.3	5.15
Debt-to-Equity	1.17-0.4	1.54+1.0	0.54+0.1	0.45+0.0	0.41+0.1	0.29+0.0	0.26+0.0	0.24
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

GRI Bio GRI

$3.4M

60 degrees pharmaceuticals, Inc. SXTP

$4.6M

Titan Pharmaceut TTNP

$6.1M

Aditxt Inc ADTX

$411K

Frequently Asked Questions

Is Palisade Bio Inc profitable?

No, Palisade Bio Inc (PALI) reported a net income of -$16.8M in fiscal year 2025.

What is Palisade Bio Inc's EBITDA?

Palisade Bio Inc (PALI) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Palisade Bio Inc's return on equity (ROE)?

Palisade Bio Inc (PALI) has a return on equity of -13.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Palisade Bio Inc's operating cash flow?

Palisade Bio Inc (PALI) generated -$10.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Palisade Bio Inc's total assets?

Palisade Bio Inc (PALI) had $134.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Palisade Bio Inc spend on research and development?

Palisade Bio Inc (PALI) invested $16.0M in research and development during fiscal year 2025.

How many shares does Palisade Bio Inc have outstanding?

Palisade Bio Inc (PALI) had 166M shares outstanding as of fiscal year 2025.

What is Palisade Bio Inc's current ratio?

Palisade Bio Inc (PALI) had a current ratio of 28.95 as of fiscal year 2025, which is generally considered healthy.

What is Palisade Bio Inc's debt-to-equity ratio?

Palisade Bio Inc (PALI) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Palisade Bio Inc's return on assets (ROA)?

Palisade Bio Inc (PALI) had a return on assets of -12.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Palisade Bio Inc's cash runway?

Based on fiscal year 2025 data, Palisade Bio Inc (PALI) had $133.4M in cash against an annual operating cash burn of $10.8M. This gives an estimated cash runway of approximately 148 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Palisade Bio Inc's Piotroski F-Score?

Palisade Bio Inc (PALI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Palisade Bio Inc's earnings high quality?

Palisade Bio Inc (PALI) has an earnings quality ratio of 0.65x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Palisade Bio Inc cover its interest payments?

Palisade Bio Inc (PALI) has an interest coverage ratio of -1805.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.